Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial

Fabio Parazzini, F Parazzini, L Fedele, Luigi Fedele, Busacca M, Mauro Busacca, M Busacca, Falsetti L, L. Falsetti, S Pellegrini, Sandra Pellegrini, Pellegrini S, Pier Luigi Venturini, Venturini PL, P. L. Venturini, Mariella Stella, M Stella, Stella M
American journal of obstetrics and gynecology · 1994 · vol. 171(5) , pp. 1205–1207 · doi:10.1016/0002-9378(94)90133-3 · PMID:7977520 · W2004606508
RCT OA: closed CC0 ⤵ 116 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This randomized trial investigated the efficacy of postsurgical medical treatment for advanced endometriosis and reported its findings.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Our purpose was to investigate the efficacy of postsurgical treatment with nafarelin in women with advanced endometriosis. STUDY DESIGN: Eligible for trial were women < or = 38 years old with unexplained infertility with or without chronic pelvic pain and stage III or IV endometriosis according to the American Fertility Society, revised, classification who underwent laparotomy as first surgical treatment for debulking or radical surgery of endometriotic lesions. Patients were assigned according to a randomization list to nasal nafarelin, 400 micrograms/day (36 subjects) or placebo nasal spray (39 subjects) for 3 months. Pelvic pain was assessed before first surgery and at the 12-month follow-up visit in women with pelvic pain by means of a multidimensional score system and a 10-point linear pain scale. RESULTS: No marked differences in pain scores emerged among women allocated to different treatments. The mean reduction of the multidimensional score was 3.6 and 4.0, respectively, in women allocated to nafarelin and placebo and of the 10-point linear scale scores was 7.0 and 6.9. These differences were not statistically significant. Within 1 year from randomization, of the 36 women allocated to nafarelin and the 39 allocated to placebo, seven (19%) and seven (18%), respectively, became pregnant. CONCLUSION: This study suggests that medical treatment with nafarelin does not markedly improve pelvic pain and short-term reproductive prognosis in women with stages III and IV endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Nafarelin Administration, Intranasal Administration, Intranasal Adult Adult Endometriosis Endometriosis Endometriosis Female Female Humans Humans Nafarelin Nafarelin Pelvic Pain Pelvic Pain Postoperative Care Postoperative Care Prognosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:14.651011+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00
License: CC0 · commercial use OK